Neurocrine Q3 Revenue Jumps 41% to $1.1B, Lifts INGREZZA Guidance
SAN DIEGO – November 02, 2026 -- Neurocrine Biosciences (Nasdaq: NBIX) grew third-quarter 2026 revenue 41% year over year to $1.1 billion, up from $795 million, and raised its full-year INGREZZA net sales guidance to $2.9 billion to $2.925 billion.
The prior INGREZZA range was $2.825 billion to $2.875 billion. Net product sales topped $1 billion for the first time, according to the company.
INGREZZA sales rise 17% to $801 million on double-digit volume growth
INGREZZA growth reflected record TRx and NRx and high persistency rates. CRENESSITY contributed $211 million, with approximately 80% reimbursement for dispensed prescriptions. VYKAT XR added $107 million.
Neurocrine acquired VYKAT XR through its purchase of Soleno Therapeutics, which closed in May 2026. The company recorded about $2.2 billion of VYKAT XR intellectual property on its balance sheet, to be amortized over an expected 16 years.